MOUNTAINEER-03
Official title
An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer
An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer
Brief Summary
Please speak with your doctor for more information
Eligibility Criteria
Please speak with your doctor for more information
Overview
Recruitment Status
Recruiting
ClinicalTrials.gov (NCT#)
NCT05253651
Trial contact
cancerclinicaltrials@sunnybrook.ca
Conditions
- Early Cancer
- Gastrointestinal Cancer